Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs

Jiaxin Hu, Keith T. Gagnon, Jing Liu, Jonathan K. Watts, Jeja Syeda-Nawaz, C. Frank Bennett, Eric E. Swayze, John Randolph, Jyoti Chattopadhyaya, David R. Corey

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

Spinocerebellar ataxia-3 (also known as Machado-Joseph disease) is an incurable neurodegenerative disorder caused by expression of a mutant variant of ataxin-3 (ATX3) protein. Inhibiting expression of ATX3 would provide a therapeutic strategy, but indiscriminant inhibition of both wild-type and mutant ATX3 might lead to undesirable side effects. An ideal silencing agent would block expression of mutant ATX3 while leaving expression of wild-type ATX3 intact. We have previously observed that peptide nucleic acid (PNA) conjugates targeting the expanded CAG repeat within ATX3 mRNA block expression of both alleles. We have now identified additional PNAs capable of inhibiting ATX3 expression that vary in length and in the nature of the conjugated cation chain. We can also achieve potent and selective inhibition using duplex RNAs containing one or more mismatches relative to the CAG repeat. Anti-CAG antisense bridged nucleic acid oligonucleotides that lack a cationic domain are potent inhibitors but are not allele-selective. Allele-selective inhibitors of ATX3 expression provide insights into the mechanism of selectivity and promising lead compounds for further development and in vivo investigation.

Original languageEnglish (US)
Pages (from-to)315-325
Number of pages11
JournalBiological Chemistry
Volume392
Issue number4
DOIs
StatePublished - Apr 2011

Fingerprint

Oligomers
Alleles
RNA
Machado-Joseph Disease
Peptide Nucleic Acids
Lead compounds
Ataxin-3
Oligonucleotides
Neurodegenerative Diseases
Nucleic Acids
Cations
Messenger RNA

Keywords

  • Allele-selective
  • Ataxin-3
  • Peptide nucleic acid
  • SiRNA
  • Spinocerebellar ataxia-3

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Molecular Biology

Cite this

Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. / Hu, Jiaxin; Gagnon, Keith T.; Liu, Jing; Watts, Jonathan K.; Syeda-Nawaz, Jeja; Bennett, C. Frank; Swayze, Eric E.; Randolph, John; Chattopadhyaya, Jyoti; Corey, David R.

In: Biological Chemistry, Vol. 392, No. 4, 04.2011, p. 315-325.

Research output: Contribution to journalArticle

Hu, J, Gagnon, KT, Liu, J, Watts, JK, Syeda-Nawaz, J, Bennett, CF, Swayze, EE, Randolph, J, Chattopadhyaya, J & Corey, DR 2011, 'Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs', Biological Chemistry, vol. 392, no. 4, pp. 315-325. https://doi.org/10.1515/BC.2011.045
Hu, Jiaxin ; Gagnon, Keith T. ; Liu, Jing ; Watts, Jonathan K. ; Syeda-Nawaz, Jeja ; Bennett, C. Frank ; Swayze, Eric E. ; Randolph, John ; Chattopadhyaya, Jyoti ; Corey, David R. / Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs. In: Biological Chemistry. 2011 ; Vol. 392, No. 4. pp. 315-325.
@article{85d3bc178b9c4bc090f4f9c1a1f019bf,
title = "Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs",
abstract = "Spinocerebellar ataxia-3 (also known as Machado-Joseph disease) is an incurable neurodegenerative disorder caused by expression of a mutant variant of ataxin-3 (ATX3) protein. Inhibiting expression of ATX3 would provide a therapeutic strategy, but indiscriminant inhibition of both wild-type and mutant ATX3 might lead to undesirable side effects. An ideal silencing agent would block expression of mutant ATX3 while leaving expression of wild-type ATX3 intact. We have previously observed that peptide nucleic acid (PNA) conjugates targeting the expanded CAG repeat within ATX3 mRNA block expression of both alleles. We have now identified additional PNAs capable of inhibiting ATX3 expression that vary in length and in the nature of the conjugated cation chain. We can also achieve potent and selective inhibition using duplex RNAs containing one or more mismatches relative to the CAG repeat. Anti-CAG antisense bridged nucleic acid oligonucleotides that lack a cationic domain are potent inhibitors but are not allele-selective. Allele-selective inhibitors of ATX3 expression provide insights into the mechanism of selectivity and promising lead compounds for further development and in vivo investigation.",
keywords = "Allele-selective, Ataxin-3, Peptide nucleic acid, SiRNA, Spinocerebellar ataxia-3",
author = "Jiaxin Hu and Gagnon, {Keith T.} and Jing Liu and Watts, {Jonathan K.} and Jeja Syeda-Nawaz and Bennett, {C. Frank} and Swayze, {Eric E.} and John Randolph and Jyoti Chattopadhyaya and Corey, {David R.}",
year = "2011",
month = "4",
doi = "10.1515/BC.2011.045",
language = "English (US)",
volume = "392",
pages = "315--325",
journal = "Biological Chemistry",
issn = "1431-6730",
publisher = "Walter de Gruyter GmbH & Co. KG",
number = "4",

}

TY - JOUR

T1 - Allele-selective inhibition of ataxin-3 (ATX3) expression by antisense oligomers and duplex RNAs

AU - Hu, Jiaxin

AU - Gagnon, Keith T.

AU - Liu, Jing

AU - Watts, Jonathan K.

AU - Syeda-Nawaz, Jeja

AU - Bennett, C. Frank

AU - Swayze, Eric E.

AU - Randolph, John

AU - Chattopadhyaya, Jyoti

AU - Corey, David R.

PY - 2011/4

Y1 - 2011/4

N2 - Spinocerebellar ataxia-3 (also known as Machado-Joseph disease) is an incurable neurodegenerative disorder caused by expression of a mutant variant of ataxin-3 (ATX3) protein. Inhibiting expression of ATX3 would provide a therapeutic strategy, but indiscriminant inhibition of both wild-type and mutant ATX3 might lead to undesirable side effects. An ideal silencing agent would block expression of mutant ATX3 while leaving expression of wild-type ATX3 intact. We have previously observed that peptide nucleic acid (PNA) conjugates targeting the expanded CAG repeat within ATX3 mRNA block expression of both alleles. We have now identified additional PNAs capable of inhibiting ATX3 expression that vary in length and in the nature of the conjugated cation chain. We can also achieve potent and selective inhibition using duplex RNAs containing one or more mismatches relative to the CAG repeat. Anti-CAG antisense bridged nucleic acid oligonucleotides that lack a cationic domain are potent inhibitors but are not allele-selective. Allele-selective inhibitors of ATX3 expression provide insights into the mechanism of selectivity and promising lead compounds for further development and in vivo investigation.

AB - Spinocerebellar ataxia-3 (also known as Machado-Joseph disease) is an incurable neurodegenerative disorder caused by expression of a mutant variant of ataxin-3 (ATX3) protein. Inhibiting expression of ATX3 would provide a therapeutic strategy, but indiscriminant inhibition of both wild-type and mutant ATX3 might lead to undesirable side effects. An ideal silencing agent would block expression of mutant ATX3 while leaving expression of wild-type ATX3 intact. We have previously observed that peptide nucleic acid (PNA) conjugates targeting the expanded CAG repeat within ATX3 mRNA block expression of both alleles. We have now identified additional PNAs capable of inhibiting ATX3 expression that vary in length and in the nature of the conjugated cation chain. We can also achieve potent and selective inhibition using duplex RNAs containing one or more mismatches relative to the CAG repeat. Anti-CAG antisense bridged nucleic acid oligonucleotides that lack a cationic domain are potent inhibitors but are not allele-selective. Allele-selective inhibitors of ATX3 expression provide insights into the mechanism of selectivity and promising lead compounds for further development and in vivo investigation.

KW - Allele-selective

KW - Ataxin-3

KW - Peptide nucleic acid

KW - SiRNA

KW - Spinocerebellar ataxia-3

UR - http://www.scopus.com/inward/record.url?scp=79955461204&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955461204&partnerID=8YFLogxK

U2 - 10.1515/BC.2011.045

DO - 10.1515/BC.2011.045

M3 - Article

VL - 392

SP - 315

EP - 325

JO - Biological Chemistry

JF - Biological Chemistry

SN - 1431-6730

IS - 4

ER -